From these results, we concluded that M-COPA overcomes EGFR-TKI resistance in NSCLC cells by downregulating the cell surface expression of both mutated EGFR and MET, which might be involved in the EGFR-bypassing alternative pathway. This evidence concerns the gene EGFR and non-small cell lung carcinoma.